NCT03567720: Intratumoral Tavo and Pembro in Patients With Inoperable Locally Advanced or Metastatic TNBC

NCT03567720
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with clinically active, unstable, progressing CNS metastases that require treatment
https://ClinicalTrials.gov/show/NCT03567720

Comments are closed.

Up ↑